Dirk Lefeber has been appointed professor of Glycosylation Disorders, with effect from 1 July 2018. Lefeber leads the research group Glycosylation Disorders in Neurology.Glycosylation is a process by which proteins are modified with different sugars. Variations in this process occur with almost every disease. Although the biological language of our DNA and proteins is already well understood, this is certainly not the case for protein glycosylation.
To gain more insight into this, Dirk Lefeber investigates patients with hereditary metabolic disorders at Radboudumc. Amongst his most important findings is the discovery of several new molecular routes for the incorporation of sugars into the muscle. Understanding such abnormalities has already led to improved diagnostics and new therapies in patient care.
VidiDirk Lefeber (Elst, 1974) studied chemistry at Utrecht University and received his MSc, with honours, in 1997. In 2001, he obtained his PhD on synthetic carbohydrate vaccines against pneumococcal bacteria. He worked as a postdoctoral researcher in infectiology at the University Medical Center Utrecht and subsequently took a staff position in the department of Neurology and the Translational Metabolic Laboratory in Nijmegen. After undertaking a four-year training programme as a laboratory specialist clinical genetics, Lefeber built a research group in the field of Glycosylation Disorders.
He is also leader of the Radboudumc Expertise Center for Disorders of Glycosylation. Lefeber has received various national and international prizes, including a Vidi grant from the NWO.
ProteinsAs professor of Glycosylation Disorders in Neurology, he will focus on the mechanisms of protein glycosylation in (hereditary) neurological diseases. The Lefeber group is developing new technologies to study the glycosylation of proteins, and will use these widely to improve medical science. Through his research, he wants to gain new insights into the process of protein glycosylation in disease, and translate these into improved person-oriented care.
Related news items
Radboud-led collaboration generates innovative candidate drug against malaria19 September 2019
A molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria. The antimalarial properties were revealed thanks to one researcher’s inspired hunch when the psoriasis drug discovery programme came to a dead end.read more
Radboud university medical center opens first healthcare AI labs19 September 2019
These are the first two ‘labs’ in the east of the Netherlands that are part of the national Innovation Center for Artificial Intelligence and the first health labs. With these two initiatives, Radboudumc and its partners are investing heavily in the application of AI to health care.read more
Careful prescription of addictive painkillers still necessary19 September 2019
Although the use of opioid painkillers in the Netherlands has risen over the past ten years, it is nowhere near the degree to which they are used in the United States, say Arnt Schellekens and his colleagues in an article published in The Lancet Public Health.read more
Exercising at home has a positive effect on Parkinson's patients19 September 2019
In a large double-blind study, Radboudumc researchers show that patients in the early stages of Parkinson's disease can exercise regularly at home for 6 months.read more